Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAtlantic Lithium Regulatory News (ALL)

If you are a professional, HNW or sophisticated investor and want to learn more about the current funding round for Peloton Minerals, please email kat.perez@focusir.com.

Share Price Information for Atlantic Lithium (ALL)

Share Price is delayed by 15 minutes
Get Live Data
15.90    0.30 (1.92%)
Bid:
15.85
Ask:
16.30
Spread: 0.45 (2.839%)
Market Cap: £127.44m
ALL Live PriceLast checked at - London Stock Exchange

Intraday Atlantic Lithium Share Chart

Update re: de-listing

1 Dec 2014 07:00

RNS Number : 3981Y
Allocate Software PLC
01 December 2014
Β 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

1 December 2014

Β 

Allocate Software Plc ("Allocate" or "Company")

Β 

- Exercise of options

- Directorate changes

- Payment of final dividend

- Cancellation of listing

Β 

Β 

Exercise of options

Β 

Allocate Software plc (AIM: ALL), the leading provider of workforce and compliance optimisation solutions today announces that 3,047,330 ordinary shares of Β£0.05 each in the capital of the Company ("New Ordinary Shares") have been issued and allotted pursuant to the exercise of certain share options under the (i) Enterprise Management Incentive Scheme; (ii) Unapproved Executive Share Option Scheme; (iii) 2010 Executive Share Option Scheme; (iv) 2010 Unapproved Share Option Scheme; (v) 2011 Long Term Retention Plan; and (vi) 2014 Bonus Option Scheme, which became exercisable in full as a result of the offer by Acorn Bidco LimitedΒ for the entire issued share capital of Allocate being declared unconditional as to acceptances on 27 November 2014.

Β 

Following the exercise of certain share options, 150,000, 233,333 and 133,333 New Ordinary Shares were issued to Ian Bowles, Allen Swann and Chris Gale respectively (or a member of their family as defined by the AIM Rules).

Β 

Application will be made to the London Stock Exchange for the 3,047,330 New Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected on 3 December 2014. The New Ordinary Shares will rank pari passu with the Company's existing ordinary shares.

Β 

Immediately prior to Admission, the total number of ordinary shares in issue was 68,305,539. The total number of ordinary shares in issue following Admission will be 71,352,869. Accordingly, the figure of 71,352,869 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

Β 

Directorate changes

Β 

Following the Annual General Meeting ("AGM") held 27 November 2014, the Company confirms that Lynn Drummond, Non-Executive Director, has resigned from the Company with immediate effect having not offered herself for re-election at the AGM. Furthermore, following the announcement on 13 February 2014 that Chris Gale intended to resign as a director of the Company, Allocate confirms that his resignation took effect from 27 November 2014.

Β 

Payment of final dividend

Β 

Further to the approval of the final dividend at the AGM, and as previously announced on 2 September 2014, the Company confirms that the dividend of 1.45 pence per ordinary share for the year ended 31 May 2014 will be paid on 5 December 2014 to shareholders on the register on 14 November 2014.

Β 

Cancellation of listing

Further to the announcement released on 27 November regarding the cancellation of trading in Allocate's Ordinary Shares on AIM, the Company can confirm that the last day of dealings will be 30 December 2014.

Β 

Enquiries:

Allocate Software Plc

Tel: +44 20 7355 5555

Ian Bowles (Chief Executive Officer)

Numis Securities Limited (broker, joint financial adviser and Nominated Adviser to Allocate)

Tel: +44 20 7260 1000

Simon Willis / Richard Thomas (Corporate Finance)

James Black (Corporate Broking)

Β 

FTI Consulting (media enquiries in respect of Allocate)

Tel: +44 20 3727 1000

Matt Dixon / Chris Lane

Β 

About Allocate Software Plc:

Β 

Allocate is the leading workforce and corporate governance software solutions provider for world-wide organisations with large, multi-skilled workforces. With a blue chip client base spanning the public and private sector, its key vertical markets include Healthcare and Defence.

Β 

The experience and in-depth knowledge gained in the UK and internationally has enabled Allocate to invest in developing innovative solutions that are relevant to the constantly evolving market needs of its customers. At the core of the business is Allocate's workforce optimisation software, which streamlines the whole workforce management of multi-disciplinary groups, across diverse locations.

Β 

Headquartered in London, Allocate provides services and support to its increasing international customer base through regional offices in the UK, Sweden, USA, Australia and Malaysia.

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IOEPGGWGGUPCGAB
Date   Source Headline
23rd Nov 20239:39 amRNSUpdated Quarterly Activities and Cash Flow Report
22nd Nov 20237:00 amRNSProject Development Update
16th Nov 20237:00 amRNSInvestor Presentation - Noosa Mining Conference
15th Nov 20237:00 amRNSRejection of Non-Binding Indicative Offers
14th Nov 20237:00 amRNSGrant of Highly Prospective Licences for Lithium
10th Nov 20237:00 amRNSConference Attendance
7th Nov 20237:00 amRNSAdditional Resource Extension Drilling Planned
1st Nov 20237:00 amRNSChange of Registered Office
31st Oct 20237:05 amRNSNotice of AGM
31st Oct 20237:00 amRNSQuarterly Activities and Cash Flow Report
20th Oct 20237:00 amRNSMining Lease Granted for Ewoyaa Lithium Project
19th Oct 202311:35 amRNSStatement re Media Speculation
13th Oct 20237:00 amRNSConference Attendance
10th Oct 20237:00 amRNSApproval to Divert Transmission Lines at Ewoyaa
29th Sep 20239:55 amRNSInvestor Presentation
28th Sep 20237:00 amRNS2023 Annual Financial Report
21st Sep 20237:00 amRNSNotice of Results and Investor Presentation
15th Sep 20237:00 amRNSConference Attendance
8th Sep 20237:05 amRNSInvestor Presentation
8th Sep 20237:00 amRNSUS$32.9m Strategic Investment
6th Sep 20237:00 amRNSResource and Exploration Drilling Results
4th Sep 20238:45 amRNSConference Attendance
30th Aug 20237:00 amRNSIssue of Equity - ESOP Options
22nd Aug 20237:00 amRNSIssue of Equity - Exercise of ESOP Options
17th Aug 20237:00 amRNSPartner Commits to Ewoyaa Development Funding
15th Aug 20237:00 amRNSMOU Signed for By-product Feldspar Study
10th Aug 20239:14 amRNSPCA Dealings
9th Aug 20239:30 amRNSDirector/PDMR Dealings
8th Aug 20237:00 amRNSResource and Exploration Drilling Results
7th Aug 20233:13 pmRNSStatement re Media Speculation
31st Jul 20237:00 amRNSQuarterly Activities and Cash Flow Report
19th Jul 20237:00 amRNSConference Attendance
13th Jul 20237:00 amRNSAppointment of Flotation Scoping Study Partner
30th Jun 20237:00 amRNSInvestor Presentation
29th Jun 20238:21 amRNSEwoyaa Definitive Feasibility Study
29th Jun 20237:17 amRNSEwoyaa Definitive Feasibility Study
23rd Jun 202311:00 amRNSBoard Appointments
20th Jun 20237:00 amRNSInitial Infill Drilling Results
16th Jun 20237:00 amRNSConference Attendance
13th Jun 20237:00 amRNSCorporate Update - Resignation of Director
1st Jun 20237:00 amRNSBoard Changes
26th May 20237:00 amRNSDTC Eligibility for OTCQX Electronic Trading
17th May 20237:00 amRNSConference Attendance
16th May 20237:00 amRNSAppointment of Chief Executive Officer
4th May 20237:00 amRNSConference Attendance
28th Apr 20237:00 amRNSQuarterly Activities and Cash Flow Report
26th Apr 20237:00 amRNSInternational Lithium Association Membership
19th Apr 20237:00 amRNSInfill Drilling and Passive Seismic Survey
6th Apr 20237:00 amRNSIssue of Equity – Exercise of ESOP Options
31st Mar 20237:00 amRNSIssue of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.